Content Conference Coverage Conferences EACS 2017
EACS 2017: New European Guidelines Cover HIV, Hepatitis C, and Related Conditions
- Details
- Category: HIV Treatment
- Created on Thursday, 30 November 2017 00:00
Everyone with HIV and hepatitis C virus (HCV) coinfection should receive direct-acting antiviral therapy for hepatitis C and should receive the same treatment regimens for hepatitis C as people with HCV monoinfection, new European guidelines issued at the 16th European AIDS Conference recommend.
EACS 2017: Fostemsavir Controls Viral Load in Half of People with Highly Drug-Resistant HIV
- Details
- Category: HIV Treatment
- Created on Thursday, 30 November 2017 00:00
Fostemsavir, a new experimental attachment inhibitor, suppressed viral load in over half of participants with extensive drug resistance when added to a background regimen selected by resistance testing, Max Lataillade of ViiV Healthcare reported at the recent 16th European AIDS Conference in Milan.
EACS 2017: Boosted Protease Inhibitor + Lamivudine Effective for HIV Maintenance Treatment
- Details
- Category: HIV Treatment
- Created on Tuesday, 31 October 2017 00:00
HIV maintenance treatment with 2 drugs, a boosted protease inhibitor and lamivudine, is just as effective as 3-drug treatment with a boosted protease inhibitor for people who already have fully suppressed viral load, according to a meta-analysis of clinical trials presented last weekat the 16th European AIDS Conference (EACS 2017) in Milan.
Coverage of the 16th European AIDS Conference
- Details
- Category: HIV Treatment
- Created on Tuesday, 14 November 2017 00:00
HIVandHepatitis.com and NAM coverage of the 16th European AIDS Conference (EACS 2017), October 25-27 2017, in Milan.
EACS 2017: ABX464 Reduces HIV Reservoir But Does Not Delay Vial Rebound
- Details
- Category: HIV Treatment
- Created on Tuesday, 31 October 2017 00:00
ABX464, a new drug that stimulates the clearance of HIV from infected cells, reduces the reservoir of HIV DNA in the body but does not delay the rebound of viral load when antiretroviral treatment is interrupted, Linos Vandekerckhove of the University of Ghent reported at the 16th European AIDS Conference (EACS 2017) last week in Milan.
More Articles...
- EACS 2017: Symtuza as Effective as Multi-Pill Combination in Previously Untreated People with HIV
- EACS 2017: European Cure Review Concentrates on HIV Therapeutic Vaccines
- EACS 2017: How a London Clinic Reduced New HIV Infections by 90%
- EACS 2017: Up to a Quarter of HIV-Negative Gay Men Attending 3 English Clinics Used PrEP in the Last Year
- EACS 2017: HIV Diagnoses in English Gay Men Have Been Falling Since 2014
- EACS 2017: High HIV Incidence from Non-Primary Partners and Low PEP and PrEP Use Seen in PARTNER Study
- EACS 2017: Survey of Dating App Users Finds that PrEP Usage Has Not Increased in Europe in the Last Year
- EACS 2017: Swiss Study Examines When Gay Men Decided to Stop Consistent Condom Use
- EACS 2017: Test-and-Treat Reduces HCV Among Gay Men in Swiss HIV Cohort
- EACS 2017: High Rate of Hepatitis C Reinfection in German Men Who Have Sex With Men
- EACS 2017: Hepatitis C Halved among Spanish People with HIV Thanks to HCV Treatment
- EACS 2017: European AIDS Clinical Society Strengthens HPV Vaccination Advice
Web Design and Development by